MindWalk Holdings (HYFT) Operating Income (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Operating Income of -$3158.0 for Q2 2026, up 76.24% year-over-year from -$1791.9 in Q2 2025, and up 82.37% quarter-over-quarter from -$17912.6 in Q1 2026.
Powered by 
Analysis
MindWalk Holdings (HYFT) Operating Income (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Operating Income for 7 consecutive years, with -$3158.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Income rose 76.24% year-over-year to -$3158.0; the TTM figure through Apr 2026 stood at -$2.0 million (up 99.94% YoY), while the FY2026 annual figure was -$26924.6, down 11.76% from the prior year.
- Operating Income improved to -$3158.0 in Q2 2026 per HYFT's latest filing, from -$17912.6 in the prior quarter.
- Across five years, Operating Income topped out at $16.6 million in Q2 2023 and bottomed at -$3.6 billion in Q3 2024.
- Historically, Operating Income has averaged -$198.5 million across 5 years, with a median of -$10561.0 in 2022.
- Annual changes were most pronounced in 2023 — Operating Income surged 590.74% — and 2024, when it slumped 117339930.13%.
- MindWalk Holdings' Operating Income stood at -$5.89 in 2022, then slumped by 35218.16% to -$2080.5 in 2023, then plunged by 142593.62% to -$3.0 million in 2024, then surged by 32.62% to -$2.0 million in 2025, then jumped by 99.84% to -$3158.0 in 2026.
- Business Quant data shows HYFT's Operating Income at -$3158.0 in Q2 2026, -$17912.6 in Q1 2026, and -$2.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 10 | MindWalk Holdings | 60.76 Mn | 52.48 Mn | 1.82 Mn | -3.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -3.16 Mn |
| Jan 31, 2026 | -2.65 Mn |
| Oct 31, 2025 | -2.00 Mn |
| Jul 31, 2025 | -3.03 Mn |
| Apr 30, 2025 | -12.34 Mn |
| Jan 31, 2025 | -17.51 Mn |
| Oct 31, 2024 | -2.97 Mn |
| Jul 31, 2024 | -3.56 Bn |
| Apr 30, 2024 | -16.47 Mn |
| Jan 31, 2024 | -2.47 Mn |
| Oct 31, 2023 | -4.26 Bn |
| Jul 31, 2023 | -5.13 Bn |
| Apr 30, 2023 | -4.49 Mn |
| Jan 31, 2023 | -3.40 Mn |
| Oct 31, 2022 | -5.89 Mn |
| Jul 31, 2022 | -7.81 Mn |
| Apr 30, 2022 | -3.38 Mn |
| Jan 31, 2022 | -2.63 Mn |
| Oct 31, 2021 | -3.56 Mn |
| Jul 31, 2021 | -2.82 Mn |